The Forecast Just Changed on Galectin Therapeutics Inc. (NASDAQ:GALT)

The Forecast Just Changed on Galectin Therapeutics Inc. (NASDAQ:GALT)


The Galectin Therapeutics Inc. (GALT) shares are trading at higher $2.86 and the avg recommendation for the stock is Moderate Buy.

To add more color to this target, the company’s high over the last year is $4.50 and the low is $1.50. Over the last 52 weeks, GALT is down -36.44% while the S&P 500 is up 1.07%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, GALT reported a profit of $22000.0. Galectin Therapeutics Inc. also saw revenues increase to $3.58 million. In addition, GALT has free cash flow of -$4.37 million as of 03-2020 The company’s EBITDA came in at -$3.58 million which compares well with its peers.

GALT Return on Equity (ROE) is -32.50%, and its Return on Assets is -29.80%. All told, it is clear that, GALT needs to be on your watchlist.

Find out when GALT reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. GALT has a short ratio of 21.43 and outstanding shares of 56.96M.

Company Outlook

GALT has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.15 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -0.30. Galectin Therapeutics Inc. GALT also noted assets of $44.11 million at the end of the last quarter. Investors should also keep an eye on sector updates as GALT has historically followed its peers on positive news.

All told, Galectin Therapeutics Inc. GALT has strung together solid data and demonstrated underlying fundamentals. At its current valuation, GALT represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Galectin Therapeutics Inc. GALT is now commanding a market cap of 157.39M and a float of 40.87M. GALT is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of GALT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in GALT, either long or short, and we have not been compensated for this article.